Colon Targeted Drug Delivery System Dissertation Meaning

1. Das S, Deshmukh R, Jha A. Role of natural polymers in the development of multiparticulate systems for colon drug targeting. Syst Rev Pharmacy. 2010;1(1):79–85. doi: 10.4103/0975-8453.59516.[Cross Ref]

2. Leuva VR, Patel BG, Chaudhary DJ, Patel JN, Modasiya MMK. Oral colon-specific drug delivery system. J Pharm Res. 2012;5(4):2293–7.

3. Kumar M, Ali A, Kaldhone P, Shirode A, Kadam VJ. Report on pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Res. 2010;3(3).

4. Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J. 2010;25(2):79–87. doi: 10.5001/omj.2010.24.[PMC free article][PubMed][Cross Ref]

5. Kumar P, Mishra B. Colon targeted drug delivery systems—an overview. Curr Drug Deliv. 2008;5(3):186–98. doi: 10.2174/156720108784911712.[PubMed][Cross Ref]

6. Malayandi R, Kondamudi P, Ruby PK, Aggarwal D. Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Deliv Transl Res. 2014;4(2):187–202. doi: 10.1007/s13346-013-0185-4.[PubMed][Cross Ref]

7. Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res. 1991;8(3):360–4. doi: 10.1023/A:1015849700421.[PubMed][Cross Ref]

8. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, et al. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res. 1990;7(7):756–61. doi: 10.1023/A:1015827908309.[PubMed][Cross Ref]

9. Ibekwe VC, Fadda HM, McConnell EL, Khela MK, Evans DF, Basit AW. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res. 2008;25(8):1828–35. doi: 10.1007/s11095-008-9580-9.[PubMed][Cross Ref]

10. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm Drug Dispos. 1990;11(6):465–75. doi: 10.1002/bdd.2510110602.[PubMed][Cross Ref]

11. Hebden JM, Blackshaw PE, Perkins AC, Wilson CG, Spiller RC. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2000;14(2):155–61. doi: 10.1046/j.1365-2036.2000.00697.x.[PubMed][Cross Ref]

12. Rana SV, Sharma S, Malik A, Kaur J, Prasad KK, Sinha SK, et al. Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease. Dig Dis Sci. 2013;58(9):2594–8. doi: 10.1007/s10620-013-2694-x.[PubMed][Cross Ref]

13. Stubbs JB, Valenzuela GA, Stubbs CC, Croft BY, Teates CD, Plankey MW, et al. A noninvasive scintigraphic assessment of the colonic transit of nondigestible solids in man. J Nucl Med. 1991;32(7):1375–81.[PubMed]

14. Christl SU, Scheppach W. Metabolic consequences of total colectomy. Scand J Gastroenterol Suppl. 1997;222:20–4.[PubMed]

15. Sandle GI. Salt and water absorption in the human colon: a modern appraisal. Gut. 1998;43(2):294–9. doi: 10.1136/gut.43.2.294.[PMC free article][PubMed][Cross Ref]

16. Schiller C, Frohlich CP, Giessmann T, Siegmund W, Monnikes H, Hosten N, et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2005;22(10):971–9. doi: 10.1111/j.1365-2036.2005.02683.x.[PubMed][Cross Ref]

17. Shameem M, Katori N, Aoyagi N, Kojima S. Oral solid controlled release dosage forms: role of GI-mechanical destructive forces and colonic release in drug absorption under fasted and fed conditions in humans. Pharm Res. 1995;12(7):1049–54. doi: 10.1023/A:1016270701021.[PubMed][Cross Ref]

18. Pijper A, Discombe G. Shape and motility of bacteria. J Pathol Bacteriol. 1946;58(3):325–42. doi: 10.1002/path.1700580302.[PubMed][Cross Ref]

19. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988;29(8):1035–41. doi: 10.1136/gut.29.8.1035.[PMC free article][PubMed][Cross Ref]

20. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther. 1989;3(6):605–13. doi: 10.1111/j.1365-2036.1989.tb00254.x.[PubMed][Cross Ref]

21. Macfarlane GT, Gibson GR, Cummings JH. Comparison of fermentation reactions in different regions of the human colon. J Appl Bacteriol. 1992;72(1):57–64.[PubMed]

22. Bown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut. 1974;15(12):999–1004. doi: 10.1136/gut.15.12.999.[PMC free article][PubMed][Cross Ref]

23. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48(4):571–7. doi: 10.1136/gut.48.4.571.[PMC free article][PubMed][Cross Ref]

24. Gibson SA, McFarlan C, Hay S, MacFarlane GT. Significance of microflora in proteolysis in the colon. Appl Environ Microbiol. 1989;55(3):679–83.[PMC free article][PubMed]

25. Rowland IR. Factors affecting metabolic activity of the intestinal microflora. Drug Metab Rev. 1988;19(3–4):243–61. doi: 10.3109/03602538808994135.[PubMed][Cross Ref]

26. Chung KT, Fulk GE, Egan M. Reduction of azo dyes by intestinal anaerobes. Appl Environ Microbiol. 1978;35(3):558–62.[PMC free article][PubMed]

27. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release. 2003;89(2):151–65. doi: 10.1016/S0168-3659(03)00126-3.[PubMed][Cross Ref]

28. Ratner BD, Gladhill KW, Horbett TA. Analysis of in vitro enzymatic and oxidative degradation of polyurethanes. J Biomed Mater Res. 1988;22(6):509–27. doi: 10.1002/jbm.820220607.[PubMed][Cross Ref]

29. Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery. Int J Pharm. 2001;224(1–2):19–38. doi: 10.1016/S0378-5173(01)00720-7.[PubMed][Cross Ref]

30. Kang M, Khanal T, Kim H, Lee D, Yeo H, Lee Y, et al. Role of metabolism by human intestinal microflora in geniposide-induced toxicity in HepG2 cells. Arch Pharm Res. 2012;35(4):733–8. doi: 10.1007/s12272-012-0418-y.[PubMed][Cross Ref]

31. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984;7(1):35–49. doi: 10.1097/00002826-198403000-00002.[PubMed][Cross Ref]

32. Azadkhan AK, Truelove SC, Aronson JK. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol. 1982;13(4):523–8.[PMC free article][PubMed]

33. Hamedani R, Feldman RD, Feagan BG. Drug development in inflammatory bowel disease: budesonide-a model of targeted therapy. Aliment Pharmacol Ther. 1997;3:98–107.[PubMed]

34. French DL, Mauger JW. Evaluation of the physicochemical properties and dissolution characteristics of mesalamine: relevance to controlled intestinal drug delivery. Pharm Res. 1993;10(9):1285–90. doi: 10.1023/A:1018909527659.[PubMed]

1. Philip AK, Dabas S, Pathak K. Optimized prodrug approach: a means for achieving enhanced anti-inflammatory potential in experimentally induced colitis. J Drug Target 2009. Apr;17(3):235-241 10.1080/10611860902718656 [PubMed][Cross Ref]

2. Oluwatoyin AO, John TF. In vitro evaluation of khaya and albizia gums as compression coating for drug targeting to the colon. J Pharm Pharmacol 2005;57:63-168 [PubMed]

3. Akala EO, Elekwachi O, Chase V, Johnson H, Lazarre M, Scott K. Organic redox-initiated polymerization process for the fabrication of hydrogels for colon-specific drug delivery. Drug Dev Ind Pharm 2003. Apr;29(4):375-386 10.1081/DDC-120018373 [PubMed][Cross Ref]

4. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 2003. Jan-Apr;6(1):33-66 [PubMed]

5. Basit A, Bloor J. Prespectives on colonic drug delivery, Business briefing. Pharmtech 2003; 185-190.

6. Watts P, Illum L. Colonic drug delivery. Drug Dev Ind Pharm 1997;23:893-913 .10.3109/03639049709148695 [Cross Ref]

7. Wood E, Wilson CG, Hardy JG. The spreading of foam and solution enemas. Int J Pharm 1985;25:191-197 .10.1016/0378-5173(85)90092-4 [Cross Ref]

8. Chien YW. Oral drug delivery and delivery systems. In: Chien YW, editor. Novel drug delivery systems. New York: Marcel Dekker Inc; 1992; 139-196.

9. Reddy SM, Sinha VR, Reddy DS. Novel oral colon-specific drug delivery systems for pharmacotherapy of peptide and nonpeptide drugs. Drugs Today (Barc) 1999. Jul;35(7):537-580 [PubMed]

10. Philip AK, Dubey RK, Pathak K. Optimizing delivery of flurbiprofen to the colon using a targeted prodrug approach. J Pharm Pharmacol 2008. May;60(5):607-613 10.1211/jpp.60.5.0006 [PubMed][Cross Ref]

11. Kulkarni SK. Pharmacology of gastro-intestinal tract (GIT). In: Kulkarni SK. editor, Handbook of experimental pharmacology. New Delhi: Vallabh Prakashan; 1999; 148-150.

12. McLeod AD, Friend DR, Tozer TN. Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: hydrolysis in rat gastrointestinal tract contents. J Pharm Sci 1994. Sep;83(9):1284-1288 10.1002/jps.2600830919 [PubMed][Cross Ref]

13. Vyas SP, Khar RK. Gastroretentive systems. In: Vyas SP, Khar RK, editors. Controlled drug delivery: concepts and advances. New Delhi: Vallabh Prakashan, 2005; 218-253.

14. Antonin KH, Rak R, Bieck PR, Preiss R, Schenker U, Hastewell J, et al. The absorption of human calcitonin from the transverse colon of man. Int J Pharm 1996;130(1):33-39 .10.1016/0378-5173(95)04248-2 [Cross Ref]

15. Fara JW. Novel Drug Delivery and its Therapeutic Application. In: Presscot LF, Nimmo WS, editors. Colonic drug absorption and metabolism. Wiley: Chichester, 1989; 103-120.

16. Mackay M, Tomlinson E. Colonic delivery of therapeutic peptides and proteins, In: Biek PR, editors. Colonic drug absorption and metabolism. New York: Marcel Dekker, 1993; 159-176.

17. Friend DR, Chang GW. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J Med Chem 1984. Mar;27(3):261-266 10.1021/jm00369a005 [PubMed][Cross Ref]

18. Rubinstein A. Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Drug Carrier Syst 1995;12(2-3):101-149 [PubMed]

19. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988. Aug;29(8):1035-1041 10.1136/gut.29.8.1035 [PMC free article][PubMed][Cross Ref]

20. Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. Crit Rev Ther Drug Carrier Syst 2001;18(5):433-458 [PubMed]

21. Ashord M, Fell JT, Attwood D, Sharma H, Woodhead P. An evaluation of pectin as a carrier for drug targeting to the colon. J Control Release 1993;26:213-220 .10.1016/0168-3659(93)90188-B [Cross Ref]

22. Fukui E, Miyamura N, Kobayashi M. An in vitro investigation of the suitability of presscoated tablets with hydroxypropylmethylcellulose acetate succinate (HPMCAS) and hydrophobicn additives in the outer shell for colon targeting. J Control Rel 200; 70:97-107. [PubMed]

23. Gazzaniga A, Iamartino P, Maffino G, Sangalli ME. Oral delayed release system for colonic specific drug delivery. Int J Pharm 1994;108:77-83 .10.1016/0378-5173(94)90418-9 [Cross Ref]

24. Fukui E, Miyamura N, Uemura K, Kobayashi M. Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int J Pharm 2000. Aug;204(1-2):7-15 10.1016/S0378-5173(00)00454-3 [PubMed][Cross Ref]

25. Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, Thomforde GM. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992. Jan;102(1):102-108 [PubMed]

26. von der Ohe MR, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 1993. Oct;329(15):1073-1078 10.1056/NEJM199310073291503 [PubMed][Cross Ref]

27. Kinget R, Kalala W, Vervoort L, van den Mooter G. Colonic drug targeting. J Drug Target 1998;6(2):129-149 10.3109/10611869808997888 [PubMed][Cross Ref]

28. Hita V, Singh R, Jain SK. Colonic targeting of metronidazole using azo aromatic polymers, development and characterization. Drug Deliv 1997;4:19-22 .10.3109/10717549709033183 [Cross Ref]

29. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm Drug Dispos 1990. Aug-Sep;11(6):465-475 10.1002/bdd.2510110602 [PubMed][Cross Ref]

30. Cummings JH, Englyst HN. Fermentation in the human large intestine and the available substrates. Am J Clin Nutr 1987. May;45(5)(Suppl):1243-1255 [PubMed]

31. Scheline RR. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 1973. Dec;25(4):451-523 [PubMed]

32. Peters R, Kinget R. Film-forming polymers for colonic drug deliver: Synthesis and physical and chemical properties of methyl derivatives of Eudragit S. Int J Pharm 1993;94:125-134 .10.1016/0378-5173(93)90016-9 [Cross Ref]

33. Huang SI, Bansleben DA, Knox JR. Biodegradable polymers: Chymotrypsin degradation of low molecular weight poly (ester-urea) containing phenylalanine. J Appl Polym Sci 1979;23:429-437 .10.1002/app.1979.070230212 [Cross Ref]

34. Swift G. Biodegradable polymers in the environment: are they really biodegradable. Proc ACS Div Poly Mat Sci Eng 1992; 66:403-404.

35. Ratner BD, Gladhill KW, Horbett TA. Analysis of in vitro enzymatic and oxidative degradation of polyurethanes. J Biomed Mater Res 1988. Jun;22(6):509-527 10.1002/jbm.820220607 [PubMed][Cross Ref]

36. Hergenrother RW, Wabewr HD, Cooper SL. The effect of chain extenders and stabilizers on the in vivo stability of polyurethanes. J Appl Biomater 1992;3:17-22 .10.1002/jab.770030104 [Cross Ref]

37. Park K, Shalaby WS, Park H, eds. Biodegradation In: Biodegradable hydrogels for drug delivery, USA: Technomic publishing company, 1993; 13-34.

38. Friend DR, Chang GW. Drug glycosides: potential prodrugs for colon-specific drug delivery. J Med Chem 1985. Jan;28(1):51-57 10.1021/jm00379a012 [PubMed][Cross Ref]

39. Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci 2003. Jan;18(1):3-18 10.1016/S0928-0987(02)00221-X [PubMed][Cross Ref]

40. Khan AK, Piris J, Truelone SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:895-896 [PubMed]

41. Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci 1983. Jul;28(7):609-615 10.1007/BF01299921 [PubMed][Cross Ref]

42. Shibasaki J, Inoue Y, Kadosaki K, Sasaki H, Nakamura J. Hydrolysis of salicyluric acid in rabbit intestinal microorganisms. J Pharmacobiodyn 1985. Dec;8(12):989-995 [PubMed]

43. Nakamura J, Kido M, Nishida K, Sasaki H. Hydrolysis of salicylic acid tyrosine salicylic acid-methionine prodrug in rabbits. Int J Pharm 1992;87:59-66 .10.1016/0378-5173(92)90227-S [Cross Ref]

44. Nakamura J, Tagami C, Nishida K, Sasaki H. Unequal hydrolysis of salicylic acid-D-alanine and salicylic acid-L-alanine conjugate in rabbit intestinal microorganisms. Chem Pharm Bull (Tokyo) 1992b Feb;40(2):547-549 [PubMed]

45. Jung YJ, Lee JS, Kim HH, Kim YM, Han SK. Synthesis and evaluation of 5-aminosalicyl-glycine as a potential colon-specific prodrug of 5-aminosalicylic acid. Arch Pharm Res 1998. Apr;21(2):174-178 10.1007/BF02974024 [PubMed][Cross Ref]

46. Simpkins JW, Smulkowski M, Dixon R, Tuttle R. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J Pharmacol Exp Ther 1988. Jan;244(1):195-205 [PubMed]

47. Cui N, Friend DR, Fedorak RN. A budesonide prodrug accelerates treatment of colitis in rats. Gut 1994. Oct;35(10):1439-1446 10.1136/gut.35.10.1439 [PMC free article][PubMed][Cross Ref]

48. Van den Mooter G, Samyn C, Kinget R. In vivo evaluation of a colon-specific drug delivery system: an absorption study of theophylline from capsules coated with azo polymers in rats. Pharm Res 1995. Feb;12(2):244-247 10.1023/A:1016283027139 [PubMed][Cross Ref]

49. Saffron M, Kumar GS, Savariora C, Burnham JC, Williams F, Neekers DC. A new approach to the oral administration of insulin and other peptide drugs. Sci 1986;233:1081-1084 .10.1126/science.3526553 [PubMed][Cross Ref]

50. Saffran M, Bedra C, Kumar GS, Neckers DC. Vasopressin: a model for the study of effects of additives on the oral and rectal administration of peptide drugs. J Pharm Sci 1988. Jan;77(1):33-38 10.1002/jps.2600770107 [PubMed][Cross Ref]

51. Saffran M, Field JB, Peña J, Jones RH, Okuda Y. Oral insulin in diabetic dogs. J Endocrinol 1991. Nov;131(2):267-278 10.1677/joe.0.1310267 [PubMed][Cross Ref]

52. Shanta KL, Ravichandran P, Rao KP. Azopolymeric hydrogels for colon targeted drug delivery. Biomat 1995;16:1313-1318 .10.1016/0142-9612(95)91046-2 [PubMed][Cross Ref]

53. Tozaki H, Fujita T, Komoike J, Kim SI, Terashima H, Muranishi S, et al. Colon-specific delivery of budesonide with azopolymer-coated pellets: therapeutic effects of budesonide with a novel dosage form against 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats. J Pharm Pharmacol 1999. Mar;51(3):257-261 10.1211/0022357991772420 [PubMed][Cross Ref]

54. Chavan MS, Sant VP, Nagarsenker MS. Azo-containing urethane analogues for colonic drug delivery: synthesis, characterization and in-vitro evaluation. J Pharm Pharmacol 2001. Jun;53(6):895-900 10.1211/0022357011776063 [PubMed][Cross Ref]

55. Tozaki H, Komoike J, Tada C, Maruyama T, Terabe A, Suzuki T, et al. Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci 1997. Sep;86(9):1016-1021 10.1021/js970018g [PubMed][Cross Ref]

56. Aiedeh K, Taha MO. Synthesis of chitosan succinate and chitosan phthalate and their evaluation as suggested matrices in orally administered colon specific drug delivery system. Arch Pharm Res 1999;332:103-107 .10.1002/(SICI)1521-4184(19993)332:3<103::AID-ARDP103>3.0.CO;2-U [PubMed][Cross Ref]

57. Rubinstein A, Radai R, Ezra M, Pathak S, Rokem JS. In vitro evaluation of calcium pectinate: a potential colon-specific drug delivery carrier. Pharm Res 1993. Feb;10(2):258-263 10.1023/A:1018995029167 [PubMed][Cross Ref]

58. Wakerly Z, Fell J, Attwood D, Parkins D. Studies on amidated pectins as potential carriers in colonic drug delivery. J Pharm Pharmacol 1997. Jun;49(6):622-625 10.1111/j.2042-7158.1997.tb06856.x [PubMed][Cross Ref]

59. Ahrabi SF, Madsen G, Dyrstad K, Sande SA, Graffner C. Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur J Pharm Sci 2000. Mar;10(1):43-52 10.1016/S0928-0987(99)00087-1 [PubMed][Cross Ref]

60. Rubinstin A, Nakar D, Sintov A. Chondroitin sulphate: A potential biodegradable carrier for colon-specific drug delivery. Int J Pharm 1992;84:141-150 .10.1016/0378-5173(92)90054-6 [Cross Ref]

61. Shun YL, Ayres JW. Calcium alginate beads as core carriers of 5-aminosalicylic acid. Pharm Res 1992;9:714-790 [PubMed]

62. Takaya T, Niwa K, Muraoka M, Ogita I, Nagai N, Yano R, et al. Importance of dissolution process on systemic availability of drugs delivered by colon delivery system. J Control Release 1998. Jan;50(1-3):111-122 10.1016/S0168-3659(97)00123-5 [PubMed][Cross Ref]

63. Muraoka M, Hu Z, Shimokawa T, Sekino S, Kurogoshi R, Kuboi Y, et al. Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. J Control Release 1998. Mar;52(1-2):119-129 10.1016/S0168-3659(97)00201-0 [PubMed][Cross Ref]

64. Jeong Y, Ohno T, Hu Z, Yoshikawa Y, Shibata N, Nagata S, Takada K. Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a dipping method. J Control Rel 71(2):175-182. [PubMed]

65. Hay DJ, Sharma H, Irving MH. Spread of steroid-containing foam after intrarectal administration. Br Med J 1979. Jun;1(6180):1751-1753 10.1136/bmj.1.6180.1751 [PMC free article][PubMed][Cross Ref]

66. Watanabe S, Kawai H, Katsuma M, Fukui M. Colon specific drug release system. U. S. Patent, 1998, 09/183339.

67. Takemura S, Watanabe S, Katsuma M, Fukui M. Human gastrointestinal treatment study of a novel colon delivery system (CODES) using scintography, Pro Int Sym Control Rel Bioact Mat 2000, 27.

68. Katsuma M, Watanabe S, Takemura S, Sako K, Sawada T, Masuda Y, et al. Scintigraphic evaluation of a novel colon-targeted delivery system (CODES) in healthy volunteers. J Pharm Sci 2004. May;93(5):1287-1299 10.1002/jps.20063 [PubMed][Cross Ref]

69. Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm 2002. Mar;235(1-2):1-15 10.1016/S0378-5173(02)00004-2 [PubMed][Cross Ref]

70. Theeuwes F, Guittared G, Wong P. Delivery of drugs to colon by oral dosage forms. U. S. Patent, 4904474

71. Swanson D, Barclay B, Wong P, Theeuwes F. Nifedipine gastrointestinal therapeutics system. Am J Med 1987;8(6):3 .10.1016/0002-9343(87)90629-2 [PubMed][Cross Ref]

72. Philip AK, Pathak K. Osmotic flow through asymmetric membrane: a means for controlled delivery of drugs with varying solubility. AAPS PharmSciTech 2006;7(3):56 10.1208/pt070356 [PMC free article][PubMed]

One thought on “Colon Targeted Drug Delivery System Dissertation Meaning

Leave a Reply

Your email address will not be published. Required fields are marked *